| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PYY |
| Uniprot No | P10082 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-97aa |
| 氨基酸序列 | MVFVRRPWPALTTVLLALLVCLGALVDAYPIKPEAPGEDASPEELNRYYA SLRHYLNLVTRQRYGKRDGPDRLLSKTFFPDGEDRPVRSRSEGPDLW |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PYY重组蛋白的3篇参考文献及其摘要概述：
1. **文献名称**: *Production and characterization of recombinant human peptide YY for obesity research*
**作者**: Batterham, R.L. et al.
**摘要**: 该研究描述了通过大肠杆菌表达系统生产重组人源PYY蛋白，并验证其生物活性。实验表明，重组PYY能有效抑制啮齿类动物的食欲，提示其在肥胖治疗中的潜在应用。
2. **文献名称**: *Expression and functional analysis of PYY analogs in regulating glucose metabolism*
**作者**: Zhang, Y. et al.
**摘要**: 研究利用哺乳动物细胞表达重组PYY类似物，发现其不仅能调控摄食行为，还能改善糖尿病模型小鼠的胰岛素敏感性，为代谢疾病治疗提供新方向。
3. **文献名称**: *Structural optimization of recombinant PYY3-36 for enhanced stability and activity*
**作者**: Smith, T.J. & Patel, K.
**摘要**: 通过基因工程技术对PYY3-36进行结构修饰，提高了重组蛋白的血清稳定性及与受体的结合能力，为开发长效型抗肥胖药物奠定基础。
(注：以上文献信息为示例性概括，具体研究需查阅实际发表的论文。)
Peptide YY (PYY), a 36-amino-acid peptide hormone, belongs to the pancreatic polypeptide (PP) family, which also includes neuropeptide Y (NPY) and pancreatic polypeptide. Discovered in 1980. PYY is primarily secreted by enteroendocrine L-cells in the distal gastrointestinal tract (ileum and colon) in response to nutrient ingestion. It plays a critical role in regulating appetite, energy homeostasis, and gastrointestinal motility through interactions with Y-family G protein-coupled receptors (Y1. Y2. Y4. Y5). The two major bioactive forms are PYY1‑36 and PYY3‑36. the latter being the predominant circulating form generated by dipeptidyl peptidase-4 (DPP-4)-mediated cleavage. PYY3‑36 exhibits high affinity for the Y2 receptor (Y2R), which mediates its anorexigenic effects via hypothalamic signaling pathways.
Recombinant PYY proteins are engineered using genetic recombination techniques, typically expressed in bacterial (e.g., E. coli) or mammalian cell systems to ensure proper folding and post-translational modifications. These proteins retain native PYY's biological activity, enabling research into its physiological roles and therapeutic potential. Interest in PYY-based therapies has grown due to its appetite-suppressing effects, positioning it as a candidate for treating obesity and metabolic disorders. Clinical studies explore PYY analogs alone or in combination with other gut hormones (e.g., GLP-1) to enhance efficacy and reduce side effects.
Challenges in therapeutic development include optimizing pharmacokinetics, minimizing enzymatic degradation, and achieving targeted receptor activation. Recombinant PYY also serves as a tool in studying gut-brain axis communication, diabetes, and intestinal diseases. Its dual role in inhibiting gastric emptying and promoting satiety underscores its multifaceted impact on metabolic regulation, driving ongoing research into precision therapies for metabolic syndromes.
×
